Evolus Inc, the company that produces the prabotulinumtoxinA-xvfs injection Jeuveau, announced that after nearly 4 years with the company, Lauren Silvernail will retire from her position as chief financial officer and executive vice president of corporate development effective May 31, 2022. The search for her successor is already underway.
“Lauren has had an incredible impact on this company, and we are grateful for her many contributions to Evolus,” said David Moatazedi, president and CEO at Evolus. “Lauren has been instrumental in helping us build this company from a development stage organization to a fast-growing and well-funded commercial business. Her experience and dedication have been key in helping Evolus get to the strong financial position we enjoy today. Lauren has been a trusted partner over the past 4 years, and we wish her the very best in retirement.”
According to the company, since joining Evolus in 2018, Silvernail assembled a high-performing team that built the commercial infrastructure to support a rapidly growing company and led the restructuring of the balance sheet and financing of the business. Most recently, she and the team successfully negotiated a $125 million credit facility that is expected to fund Evolus through cash flow breakeven, removing the need for further financing of its current operations and positioning the company for continued success.
“It has been a privilege to work alongside such a talented and dedicated group of individuals, and I am excited to embark on this next chapter of my life,” said Silvernail. “I leave knowing the company is in a very strong financial position, with an outstanding leadership team to guide it. I look forward to seeing Evolus execute its growth strategy to become a leading, multi-product aesthetic company.”